Archive:
Im Kurzinterview: Dr. Andreas Ludäscher, Geschäftsführer Pfizer Pharma PFE GmbH und Deutschlandchef von Pfizer Essential Health
04.06.2018
The “Opportunities and risks for biosimilars in Germany” were the focus of the satellite symposium organized by Pfizer on the occasion of the capital city congress “Medicine and Health 2018”. The experts agreed – Prof. Dr. Diana Lüftner (Charité University Medicine, Berlin), Prof. Dr. Jürgen Wasem (University of Duisburg-Essen), Prof. Dr. Uwe May (Fresenius University, Idstein), Enno Scheel (Federal Association of Recipe Manufacturers) and Dr. Andreas Ludäscher (Pfizer Pharma PFE GmbH/Pfizer Essential Health) – that patients can only receive sustainable and economical care if the control instruments in the statutory health insurance drug market are synchronized; whereby – according to May – there is “a need for legislative clarification” in order to “avoid distortions and false incentives in the market”.
04.06.2018
With eleven key actions within the “Biosimilar Action Plan” (BAP), the American Food and Drug Administration (FDA) wants to promote not only innovation, but also competition between biologics and the development of biosimilars. Likewise, the measures are intended to help not only to establish a more competitive market, but also to create greater incentives for companies to support investments required for future products that are intended to bring greater benefits to patients and public health after the patent expires . According to the Commissioner appointed by US President Donald Trump in 2017, Dr. Scott Gottlieb, will focus on further developing guidelines “that make the process for developing biosimilars more efficient.”
04.06.2018
Sanofi hosted an offline/online panel discussion on real-world evidence (RWE) at the 78th Annual Meeting of the American Diabetes Association (ADA) in Orlando, Florida. The stated goal was to raise awareness and foster a better understanding of RWE. Internationally active Sanofi scientists explained and discussed the potential enrichment of the RCT-based evidence base through RWE, as well as the new, resulting insights into the efficacy of Toujeo compared to first- and second-generation basal insulins and its impact on hypoglycemia reduction.
04.06.2018
Die Anforderungen an die Arzneimittelverordung haben sich vor allem durch die Auswirkungen des demographischen Wandels und der damit einhergehenden zunehmenden Multimorbidität in den letzten Jahrzehnten dramatisch verändert. In dieser Zeit neuer Herausforderungen in der Arzneimittelverordnung war es Ziel des Kongresses „Die Lage der Arzneimittelanwendung 2018“– veranstaltet vom Verein zur Förderung der Arzneimittel-Anwendungsforschung e.V., dem Hartmannbund und der Robert Bosch Stiftung in Kooperation mit dem Institut für Gesundheitssystem-Entwicklung – den Status Quo zu beschreiben, notwendige Entwicklungen aufzuzeigen und Wege zu benennen.
04.06.2018
According to its supporters, a uniform fee schedule for outpatient care is primarily aimed at reducing what they believe to be the “two-tier medicine” that exists in the German healthcare system. According to this, the two currently existing fee schedules, due to their different remuneration for the same services, mean that privately insured people have better access to outpatient medical care than those with statutory health insurance through shorter waiting times for doctor's appointments. At the same time, this dual remuneration system tends to encourage oversupply among privately insured people and contributes to the endangerment of comprehensive, high-quality healthcare in statutory health insurance (GKV). Replacing the dual remuneration system with a uniform fee schedule can, as most supporters wish, represent a relevant step towards citizens' insurance with income-dependent contributions like in the GKV, but it can also be carried out as an isolated measure and thus analyzed from health economic aspects.
04.06.2018
Around 30% of the Innovation Fund's applications are approved - a fairly high success rate compared to other funding providers. Rejections can have various reasons - from formal errors, to deficiencies in content, to political or monetary factors. Now it could well be that the almost 70% of rejected applications contain some or even many project ideas and approaches that are forever removed from the goal of better care; at least if the negative applicants do not find the courage to resubmit their project in the next wave of calls for proposals from the Innovation Fund or to other third-party funding sources. Anyone who is thinking about an Innovation Fund 2.0, as Federal Health Minister Jens Spahn announced at the G-BA congress “Two Years of Innovation Fund” (see MVF 04/18), is not only allowed 200 million (instead of the previous 300 million) euros for further years want to get their hands on insurance money, but also have to think about how they can be used better (possibly better than before) and what the central adjustment screws look like to achieve this.
04.06.2018
If you look outside the Bauhaus-style building that houses the Institute for Health Services Research and Clinical Epidemiology of the Faculty of Medicine at the Philipps University of Marburg, you see green, green and more green - that of the New Garden of the Botanical Gardens the Philipps University on the Lahnberge. The ten-person team led by Prof. Dr. works in this beautiful environment - closely linked to the Marburg University Hospital. med. Max Geraedts, which is primarily concerned with the analysis of determinants of the functionality of healthcare systems and their components.
04.06.2018
The German Society for Integrated Care in Health Care, which has existed for over 15 years. V. (DGIV) has certainly not set itself a simple end in itself. It wants to promote the “consistent, thoroughgoing and sustainable implementation of the principle of integrated care” as one of the main prerequisites for improving the efficiency of our health system and has been discussing this for decades at its federal congresses: at the end of last year with particular attention to the tasks for the “ Federal-state working group on cross-sector care”, the results of which – according to DGIV board chairman Prof. Dr. Stefan G. Spitzer – “should probably form the basis for larger health policy reforms in this area”.
04.06.2018
The IGiB GbR (Innovative Health Care in Brandenburg) has set itself the goal of ensuring medical care, especially in rural regions. To this end, it is developing new care models and structures. It was founded in 2009 by the then AOK Brandenburg and the Brandenburg Association of Statutory Health Insurance Physicians (KVBB). Barmer joined in 2010. IGiB managing director Lutz O. Freiberg answers questions about the past, present and future of IGiB GbR in an interview.